Literature DB >> 1912517

MHC antigens in human melanomas.

D J Ruiter1, V Mattijssen, E B Broecker, S Ferrone.   

Abstract

The distribution of MHC antigens in human melanocytic lesions, i.e. HLA class I and HLA class II antigens is reviewed. HLA class I antigens have a broad distribution, but may be lost during tumor progression. In contrast, HLA class II antigen expression appears with neoplastic transformation. The mode of regulation of HLA antigens in melanoma lesions is complex. Immunohistochemical demonstration of HLA antigen expression in primary melanoma lesions and in locoregional metastases has prognostic relevance. Expression of HLA-DR in primary melanoma lesions is associated with an unfavorable prognosis, as is a decreased expression of HLA-A,B,C antigens in locoregional metastases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912517

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  26 in total

Review 1.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

2.  HLA expression in a primary uveal melanoma, its cell line, and four of its metastases.

Authors:  D J Blom; L R Schurmans; I De Waard-Siebinga; D De Wolff-Rouendaal; J E Keunen; M J Jager
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

3.  Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.

Authors:  Chiara Camisaschi; Annamaria De Filippo; Valeria Beretta; Barbara Vergani; Antonello Villa; Elisabetta Vergani; Mario Santinami; Antonello Domenico Cabras; Flavio Arienti; Frédéric Triebel; Monica Rodolfo; Licia Rivoltini; Chiara Castelli
Journal:  J Invest Dermatol       Date:  2014-01-17       Impact factor: 8.551

Review 4.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

5.  Melanoma, immune surveillance, and immunotherapy.

Authors:  S Ferrone
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

6.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

7.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; T B Simonis; A Abati; J Hackett; T O'Dea; P Fetsch; J Yannelli; N P Restifo; J J Mulé
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-07

8.  Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA.

Authors:  Z Wang; Y Cao; A P Albino; R A Zeff; A Houghton; S Ferrone
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

9.  Differential gene expression in human glioma cells: correlation with presence or absence of DNA-dependent protein kinase.

Authors:  Rong Ai; Ana Sandoval; Paul Labhart
Journal:  Gene Expr       Date:  2003

10.  On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Authors:  M R Bernsen; L Håkansson; B Gustafsson; L Krysander; B Rettrup; D Ruiter; A Håkansson
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.